Jonas Ellenberg, Ph.D.

Jonas Ellenberg joined the biostatistics faculty at the University of Pennsylvania in the fall of 2004 as Professor of Biostatistics and as Associate Dean for Research Program Development in the School of Medicine. Dr. Ellenberg’s collaborative research has focused on neurological diseases, and more recently, HIV/AIDS. He spent 26 years at the National Institute of Neurological Diseases and Stroke, NIH, 11 of those as Chief of the Biometry Branch. With medical colleagues, he performed extensive analyses of the Collaborative Perinatal Project, a longitudinal study intended to identify the etiology of serious childhood neurological illnesses and conditions. In addition to major medical findings related to causes of cerebral palsy and the significance of febrile seizures, this collaborative work led to important methodological insights regarding the conduct of longitudinal research, particularly relating to selection bias and generalizability of study results. Dr. Ellenberg is currently the Co-PI for the COAG study, to evaluate the use of genetic guided dosing of Warfarin for use in anticoagulation and the Co-PI for the Prematurity and Respiratory Outcomes (PROP) observational follow up study. From 1995 to 2004 Dr. Ellenberg served as Vice President of Westat, Inc., and headed its Biostatistics Group. His collaborative research during this period focused on HIV in adolescents. He is an elected fellow of the ASA and the AAAS, and an elected member of the International Statistical Institute. Dr. Ellenberg served as President of the American Statistical Association in 1999 and the International Biometric Society in 1988.

Selected Publications

  • Orsey AD, Belasco JB, Ellenberg JH, Schmitz KH, Feudtner C. Variation in receipt of opioids by pediatric
    oncology patients who died in children's hospitals. Pediatric Blood and Cancer 52:761-766, 2009.
  • Ellenberg JH, The National Children's Study (NCS). Establishment and protection of the inferential base. Statistics In Medicine 29:1360-1367, 2010.
  • Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH. Prospective alpha allocation in the
    clarification of optimal anticoagulation through genetics (COAG) trial. Clinical Trials 7(5):697-704, 2010.
  • French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg
    JH, Anticoagulation Through Genetics Investigators Coag Clarification Of Optimal: Statistical design of
    personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics
    (COAG) trial. Trials 11(1):108, Nov 2010.
  • Wade KC, Ellenberg JH, Grosser T, Brensinger CM, Kimmel SE, Hennessy S: Exogenous estrogen
    does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal
    women. J Cardiovasc Pharmacol 57(2):194-200, Feb 2011.